Simulations Plus, Inc. (SD3.F)

37,00 0,00 (0,00%) Börsenschluss: 04:12PM CEST

Simulations Plus, Inc.

42505 Tenth Street West
Lancaster, CA 93534-7059
United States
661 723 7723
https://www.simulations-plus.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 192

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Walter S. Woltosz M.A.S., M.S.	Co-Founder & Chairman	74,64k	N/A	1945
Mr. Shawn M. O'Connor	Chief Executive Officer	790,83k	N/A	1960
Mr. William Frederick	COO, CFO & Secretary	413,46k	1,21k	1964
Mr. John Anthony DiBella M.S.	President of PBPK & Cheminformatics Solutions	373,04k	1,99M	1980
Dr. Brett A. Howell Ph.D.	President of Quantitative Systems Pharmacology Solutions	300,13k	N/A	1984
Ms. Jill Fiedler-Kelly M.S.	President of Clinical Pharmacology & Pharmacometrics Services	367,41k	16,26k	1969
Ms. Viera Lukacova Ph.D.	Chief Science Officer	N/A	N/A	N/A
Dr. Bud Nelson J.D., Ph.D.	VP of Corporate Counsel & Personal Data Protection Officer	N/A	N/A	N/A
Ms. Arlene Padron	Corporate Director of Marketing	N/A	N/A	N/A
Dr. Scott Q. Siler	Chief Scientific Officer of DILIsym Services, Inc	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Corporate Governance

Simulations Plus, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 2. Die grundlegenden Scores sind Audit: 2, Vorstand: 5, Shareholderrechte: 1, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.